Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 1843-1851, 2009. First published August 20, 2009; 10.1373/clinchem.2009.129940
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2009.129940v1
55/10/1843    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Le Pottier, L.
Right arrow Articles by Daridon, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Le Pottier, L.
Right arrow Articles by Daridon, C.
(Clinical Chemistry. 2009;55:1843-1851.)
© 2009 American Association for Clinical Chemistry, Inc.

Clinical Immunology

New ELISA for B Cell–Activating Factor

Laëtitia Le Pottier1, Boutahar Bendaoud2, Yves Renaudineau1,2, Pierre Youinou1,2,a, Jacques-Olivier Pers1,2 and Capucine Daridon1

1 EA 2216 "Immunologie et Pathologie" and IFR 418 ScInBioS, Université de Brest, Brest, France, and Université Européenne de Bretagne, Rennes, France; 2 Brest University Medical School Hospital (CHU Augustin Morvan), Brest, France.

aAddress correspondence to this author at: Laboratory of Immunology, Brest University Medical School Hospital, BP824, F29609, Brest, France. Fax +33-298-22-38-47; e-mail youinou{at}univ-brest.fr.

Background: The B cell–activating factor of the TNF family (BAFF) is upregulated in autoimmune diseases, but a number of conflicting results have cast doubts on the reliability of the ELISA protocols currently used for its quantification. This situation led us to develop a new ELISA for the measurement of BAFF.

Methods: BAFF was purified for use alongside nonglycosylated recombinant BAFF. Two monoclonal antibodies (mAbs) and two polyclonal antibodies (pAbs) to BAFF were used.

Results: The optimization process showed that the pAb format was preferable to the mAb format as capture antibody, because the pAbs recognized the glycosylated as well as the nonglycosylated forms of BAFF. The most efficient pair of Abs involved using the unconjugated form of a goat pAb to capture BAFF and the same biotinylated goat pAb to detect bound BAFF. This ELISA was not influenced by the presence of rheumatoid factor.

Conclusions: This new ELISA helped provide insights into why serum concentrations of BAFF vary between studies for a given population of patients. It is a reliable tool for the management of the diseases in which BAFF is an indication of response to therapy.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.